No: 2017/SEC/NOV/165

November 23, 2017

National Stock Exchange of India Limited
“Exchange Plaza”, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex
Bandra (East), Mumbai – 400051

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001

NSE - Symbol - BIOCON

BSE - Scrip code - 532523

Dear Sir,

Sub: Press Release titled “Biocon Launches KRABEVA™- Biosimilar Bevacizumab for Treating Several Types of Cancer in India.”

In compliance with the provisions of regulation 30 of SEBI (Listing Obligations and Disclosure Requirement) Regulations 2015, please find enclosed herewith, the subject press release being issued by the Company today.

Kindly take on record the same.

Thanking You,

For BIOCON LIMITED

[Signature]

Dr. Arun S Chandavarkar
Chief Executive Officer and Joint Managing Director
Press Release

Biocon Launches KRABEVA™- Biosimilar Bevacizumab for Treating Several Types of Cancer in India

Bengaluru, India, Nov 23, 2017:

Biocon Ltd (BSE code: 532523, NSE: BIOCON), Asia’s premier biopharmaceuticals company, has launched KRABEVA™, a biosimilar Bevacizumab for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers, in India.

KRABEVA™, a monoclonal antibody (mAb) developed by Biocon, will help expand access to a world class, high quality biosimilar Bevacizumab for cancer patients in India. It is the world’s first and only Bevacizumab with a unique ‘Qual-Check’ mechanism, which will ensure that patients get a quality-ascertained product right upto infusion.

Bevacizumab is indicated as a first-line treatment of patients with metastatic colorectal cancer (mCRC), and is accepted as a standard treatment option in combination with chemotherapy for patients with non-small-cell lung cancer (NSLC), metastatic renal cell carcinoma and recurrent ovarian cancer.

Dr Arun Chandavarkar, CEO & Joint Managing Director, Biocon said: “With KRABEVA™ we intend to provide a high quality, world-class biosimilar Bevacizumab as an affordable therapy option for patients of various types of cancer. We believe KRABEVA™ will be an important addition to our Oncology portfolio of novel biologics as well as biosimilars, which are making a significant impact in the realm of cancer care in India.”

KRABEVA™ is the second key oncologic biosimilar product from Biocon’s global biosimilars portfolio to be launched in India, in order to address the unmet patient need for affordable biological therapies. It is being offered to patients at an MRP of Rs 24,000 for 100 mg / 4 ml vials and Rs 39,990 for 400 mg / 16 ml vials, making it a high quality affordable alternative to the innovator brand.

KRABEVA™ is being launched post successful completion of Phase III clinical trials and approval of Biocon’s Marketing Authorization Application by the Drug Controller General of India (DCGI).
Most biologic products require a specific storage condition to maintain the safety, purity and potency of the drug. An efficient and seamless cold chain prevents denaturation of antibodies due to heat. KRABEVA™ is being introduced with an innovative temperature-sensitive packaging that includes thermo-chronic stickers, which change colour irreversibly if the cold chain temperature is not maintained. This first-of-its-kind ‘Qual Check’ feature ensures quality check of the product up to the point of administration to the patient. This will provide greater confidence to pharmacists, nurses and caregivers about the quality of the product they are dispensing and will enable better patient safety.

Clinical Development
Biocon’s biosimilar Bevacizumab has been developed for global markets with a clear focus to meet strict quality and regulatory requirements and provide access to a high quality biosimilar to patients.

The Phase III clinical study involving 146 patients of mCRC, has been conducted after obtaining regulatory approvals in India. The extrapolation to other indications has been approved by the DCGI.

The global Phase III trial in non-small-cell lung cancer (NSLC) patients is being conducted at more than 100 sites across multiple countries using an EU and US sourced reference product. Prior to this, a three-way Phase I PK study in healthy volunteers was conducted in Europe.

MoA of Bevacizumab - Antiangiogenesis Targeted Therapy
Bevacizumab is a monoclonal antibody (mAb) targeting Vascular Endothelial Growth Factor-A (VEGF-A), a cell protein that induces growth of blood vessels that feed tumors. By blocking this protein, Bevacizumab cuts the supply of food and oxygen to the tumor, thus starving it. Bevacizumab is prescribed in the treatment of several cancers including metastatic colorectal cancer, ovarian cancer, advanced non-small-cell lung cancer, recurrent glioblastoma, cervical cancer and renal cancer.

Addressing the Cancer Challenge
The launch of KRABEVA™, biosimilar Bevacizumab, comes at a time when the incidence of cancer is projected to reach alarming numbers, with over 17.3 lakh new cases of cancer and over 8.8 lakh cancer deaths projected in India by 2020 as per the Indian Council of Medical Research (ICMR).

An estimated 64,000 cases of colorectal cancer were diagnosed and 49,000 deaths recorded due to the disease in India, according to GLOBOCAN’s 2012 estimates of the worldwide incidence and mortality from cancers.
There were an estimated 1.14 lakh new lung cancer cases in India in 2016 and the number is projected to grow to 1.40 lakh by 2020, according to ICMR. Similarly, new cervical cancer cases are expected to rise from an estimated 1 lakh in 2016 to about 1.04 lakh by 2020.

Global sales of the innovator product in 2016 were pegged at USD 6.9 billion. The market size for Bevacizumab, both innovator product and biosimilars, in India is estimated at Rs 177 Crore (USD 27 million), according to IPSOS June MAT 2017 data.

About Biocon

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE3766G1013) is India's largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global biopharmaceutical enterprise serving customers in over 120 countries, it is committed to reduce therapy costs of chronic diseases like diabetes, autoimmune and cancer. Through innovative products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. It has successfully developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from 'Lab to Market'. Some of its key brands are INSUGEN® (rh-insulin), BASALOG® (Glargine), CANMAB™ (Trastuzumab), BIOMAb-EGFR™ (Nimotuzumab) and ALZUMAb™ (Itolizumab), a ‘first in class’ anti-CD6 monoclonal antibody. It has a rich pipeline of Biosimilars and Novel Biologics at various stages of development including Insulin Tregopil, a high potential oral insulin analog.

Visit: www.biocon.com Follow us on twitter: @bioconlimited

For More Information Contact:

<table>
<thead>
<tr>
<th>Media Relations</th>
<th>Investor Relations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seema Ahuja</td>
<td>Saurabh Palliwal</td>
</tr>
<tr>
<td>VP &amp; Global Head, Corporate Communications</td>
<td>Head, Investor Relations</td>
</tr>
<tr>
<td>☏ +91 80 2808 2222</td>
<td>☏ +91 80 6775 2040</td>
</tr>
<tr>
<td>☏ +91 99723 17792</td>
<td>☏ +91 95383 80801</td>
</tr>
<tr>
<td>☐ <a href="mailto:seema.ahuja@biocon.com">seema.ahuja@biocon.com</a></td>
<td>☐ <a href="mailto:saurabh.palliwal@biocon.com">saurabh.palliwal@biocon.com</a></td>
</tr>
</tbody>
</table>

DISCLAIMER: This Press Release may include forward-looking information to enable investors to comprehend our prospects and take informed investment decisions. The statements - written and oral - that we periodically make contain forward looking statements that set out anticipated results based on the management’s plans and assumptions. We have tried wherever possible to identify such statements by using words such as ‘anticipates’, ‘estimates’, ‘expects’, ‘projects’, ‘intends’, ‘plans’, ‘believes’ and words of similar substance in connection with any discussion of future performance. The market data & rankings used, are based on several published reports and internal company assessment. We cannot guarantee that these forward-looking statements will be realized, although we believe we have been prudent in our assumptions. The achievement of results is subject to risks, uncertainties and even inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated or projected. Readers should bear this in mind. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.